Towards standardized human platelet lysate production in Europe: An initiative of the European Blood Alliance

European Blood Alliance, Dirk De Korte, Willem Delabie, Hendrik B Feys*, Thomas Klei, Rune Larsen, Ólafur Sigurjónsson, Ana Paula Sousa

*Corresponding author af dette arbejde

Publikation: Bidrag til tidsskriftArtikelForskningpeer review

Abstract

Human platelet lysate (hPL) is a supplement for cell culture media that can be derived from platelet concentrates. As not-for-profit blood establishments, we endorse the evolution of maximally exploiting the potential of donated blood and its derived components, including platelets. The decision to use platelet concentrates to supply hPL as a cell culture supplement should align with the principles and values that blood establishments hold towards the use of donated blood components in transfusion. As a consequence, questions on ethics, practical standardization of hPL production and logistics as well as on assuring hPL quality and safety need careful consideration. We therefore propose an opinion on some of these matters based on available literature and on discussions within the proceedings of the Working Group on Innovation and New Products of the European Blood Alliance. In addition, we propose collaboration among European blood establishments to streamline efforts of hPL supply to maximize the potential of hPL and its application in the wider field of medicine.

OriginalsprogEngelsk
Sider (fra-til)79-87
Antal sider9
TidsskriftVox Sanguinis
Vol/bind119
Udgave nummer1
Tidlig onlinedato4 dec. 2023
DOI
StatusUdgivet - jan. 2024

Bibliografisk note

© 2023 International Society of Blood Transfusion.

Fingeraftryk

Udforsk hvilke forskningsemner 'Towards standardized human platelet lysate production in Europe: An initiative of the European Blood Alliance' indeholder.

Citationsformater